This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moore, J P Articles by Burkly, L C Search for Related Content PubMed PubMed Citation Articles by Moore, J P Articles by Burkly, L C

A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.

Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom.

ABSTRACT

The murine monoclonal antibody (MAb) 5A8, which is reactive with domain 2 of CD4, blocks human immunodeficiency virus type 1 (HIV-1) infection and syncytium formation of CD4+ cells (L. C. Burkly, D. Olson, R. Shapiro, G. Winkler, J. J. Rosa, D. W. Thomas, C. Williams, and P. Chisholm, J. Immunol., in press). Here we show that, in contrast to the CD4 domain 1 MAb 6H10, 5A8 and its Fab fragment do not block soluble CD4 (sCD4) binding to virions, whereas they do inhibit sCD4-induced exposure of cryptic epitopes on gp41 and dissociation of gp120 from virions. Two other MAbs, OKT4 and L120, which are reactive with domains 3 and 4 of CD4, have little or no effect on HIV-1 infection, syncytium formation, or sCD4-induced conformational changes in the envelope glycoproteins. The mechanisms of action of 5A8 and 6H10 can be further distinguished in syncytium inhibition assays: 6H10 blocks competitively, while 5A8 does not. We opine that 5A8 blocks HIV-1 infection and fusion by interfering with conformational changes in gp120/gp41 and/or CD4 that are necessary for virus-cell fusion.

This article has been cited by other articles:

• Zhang, X.-Q., Sorensen, M., Fung, M., Schooley, R. T. (2006). Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20).. Antimicrob. Agents Chemother. 50: 2231-2233 [Abstract] [Full Text]  
• Briz, V., Poveda, E., Soriano, V. (2006). HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619-627 [Abstract] [Full Text]  
• Mack, M., Pfirstinger, J., Haas, J., Nelson, P. J., Kufer, P., Riethmuller, G., Schlondorff, D. (2005). Preferential Targeting of CD4-CCR5 Complexes with Bifunctional Inhibitors: A Novel Approach to Block HIV-1 Infection. J. Immunol. 175: 7586-7593 [Abstract] [Full Text]  
• Biswas, P., Mantelli, B., Sica, A., Malnati, M., Panzeri, C., Saccani, A., Hasson, H., Vecchi, A., Saniabadi, A., Lusso, P., Lazzarin, A., Beretta, A. (2003). Expression of CD4 on human peripheral blood neutrophils. Blood 101: 4452-4456 [Abstract] [Full Text]  
• Margolin, D. H., Helmuth Saunders, E. F., Bronfin, B., de Rosa, N., Axthelm, M. K., Alvarez, X., Letvin, N. L. (2002). High Frequency of Virus-Specific B Lymphocytes in Germinal Centers of Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J. Virol. 76: 3965-3973 [Abstract] [Full Text]  
• Hu, Q.-x., Barry, A. P., Wang, Z.-x., Connolly, S. M., Peiper, S. C., Greenberg, M. L. (2000). Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis. J. Virol. 74: 11858-11872 [Abstract] [Full Text]  
• Reeves, J. D., Hibbitts, S., Simmons, G., McKnight, A., Azevedo-Pereira, J. M., Moniz-Pereira, J., Clapham, P. R. (1999). Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo. J. Virol. 73: 7795-7804 [Abstract] [Full Text]